Who are Tamsulosin and Tadalafil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tamsulosin-and-tadalafil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tamsulosin and Tadalafil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamsulosin and Tadalafil (Tamsulosin and Tadalafil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1A adrenergic antagonist and phosphodiesterase-5 inhibitor combination. Area: Urology.

marketed Alpha-1A adrenergic antagonist and phosphodiesterase-5 inhibitor combination Alpha-1A adrenergic receptor; phosphodiesterase-5 (PDE-5) Urology Small molecule Live · refreshed every 30 min

Target snapshot

Tamsulosin and Tadalafil (Tamsulosin and Tadalafil) — Fayoum University Hospital. Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate to relax smooth muscle, while tadalafil inhibits phosphodiesterase-5 to increase cGMP and improve erectile function and lower urinary tract symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamsulosin and Tadalafil TARGET	Tamsulosin and Tadalafil	Fayoum University Hospital	marketed	Alpha-1A adrenergic antagonist and phosphodiesterase-5 inhibitor combination	Alpha-1A adrenergic receptor; phosphodiesterase-5 (PDE-5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1A adrenergic antagonist and phosphodiesterase-5 inhibitor combination class)

Fayoum University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tamsulosin and Tadalafil — Competitive Intelligence Brief. https://druglandscape.com/ci/tamsulosin-and-tadalafil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab